Search Results - "HARMSZE, A. M."

Review of global regulations concerning biowaivers for immediate release solid oral dosage forms by Gupta, E., Barends, D.M., Yamashita, E., Lentz, K.A., Harmsze, A.M., Shah, V.P., Dressman, J.B., Lipper, R.A.

“…The regulations with respect to biowaivers for immediate release (IR) solid oral dosage forms in the USA, the EU, Japan and from the World Health Organization…”
Get full text

Variability in on-treatment platelet reactivity explained by CYP2C192 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting by Bouman, Heleen J, Harmsze, Ankie M, van Werkum, Jochem W, Breet, Nicoline J, Bergmeijer, Th O, Ten Cate, Hugo, Hackeng, Christian M, Deneer, Vera H M, Ten Berg, Jurriën M

“…An inadequate response to clopidogrel is mainly attributable to the variable formation of its active metabolite. The CYP2C19*2 loss-of-function polymorphism…”
Get more information

The use of the VerifyNow system to monitor antiplatelet therapy: A review of the current evidence by van Werkum, J. W., Harmsze, A. M., Elsenberg, E. H. A. M., Bouman, H. J., ten Berg, J. M., Hackeng, C. M.

“…Multiple studies have demonstrated the effectiveness of dual or triple antiplatelet therapy with aspirin, clopidogrel and glycoprotein (GP) IIb/IIIa therapy in…”
Get full text

Combined influence of proton‐pump inhibitors, calcium‐channel blockers and CYP2C192 on on‐treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention by HARMSZE, A. M., VAN WERKUM, J. W., SOUVEREIN, P. C., BREET, N. J., BOUMAN, H. J., HACKENG, C. M., RUVEN, H. J. T., TEN BERG, J. M., KLUNGEL, O. H., DE BOER, A., DENEER, V. H. M.

“…Background: The carriage of CYP2C19*2 and the use of proton‐pump inhibitors (PPIs) and calcium‐channel blockers (CCBs) has been associated with the diminished…”
Get full text

Effect of gender difference on platelet reactivity by Breet, N. J., Sluman, M. A., van Berkel, M. A. J. P. J., van Werkum, J. W., Bouman, H. J., Harmsze, A. M., Kelder, J. C., Zijlstra, F., Hackeng, C. M., ten Berg, J. M.

“…Background Previous studies have suggested that women do not accrue equal therapeutic benefit from antiplatelet medication as compared with men. The…”
Get full text

CYP2C192 and CYP2C93 alleles are associated with stent thrombosis: a case–control study by Harmsze, Ankie M., van Werkum, Jochem W., ten Berg, Jurriën M., Zwart, Bastiaan, Bouman, Heleen J., Breet, Nicoline J., van 't Hof, Arnoud W.J., Ruven, Hendrik J.T., Hackeng, Christian M., Klungel, Olaf H., de Boer, Anthonius, Deneer, Vera H.M.

“…Aims Despite treatment with clopidogrel on top of aspirin, stent thrombosis (ST) still occurs being the most serious complication after percutaneous coronary…”
Get full text

High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention by Breet, Nicoline J, van Werkum, Jochem W, Bouman, Heleen J, Kelder, Johannes C, Harmsze, Ankie M, Hackeng, Christian M, ten Berg, Jurriën M

“…High on-clopidogrel platelet reactivity (HCPR) and high on-aspirin platelet reactivity (HAPR) are associated with atherothrombotic events following coronary…”
Get more information

The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response by Harmsze, Ankie M, Robijns, Karen, van Werkum, Jochem W, Breet, Nicoline J, Hackeng, Christian M, Ten Berg, Jurrien M, Ruven, Hendrik J T, Klungel, Olaf H, de Boer, Anthonius, Deneer, Vera H M

“…Clopidogrel is a prodrug that has to be converted in vivo to its active metabolite by cytochrome (CYP)P450 iso-enzymes. As calcium channel blockers (CCBs) are…”
Get more information

Prolonged diminished effect of coumarin derivatives after use of rifampicin by Harmsze, A M, Deneer, V H M, Wiltink, E H

“…A 73-year-old woman with endocarditis was treated with flucloxacillin and rifampicin. She already used the anticoagulant acenocoumarol because of a recent…”
Get more information

The use of the Verify Now system to monitor antiplatelet therapy: A review of the current evidence by van Werkum, J. W., Harmsze, A. M., Elsenberg, E. H. A. M., Bouman, H. J., ten Berg, J. M., Hackeng, C. M.

Get full text

Oxybutynin therapy for generalized hyperhidrosis by Tupker, Ron A, Harmsze, Ankie M, Deneer, Vera H M

Get more information

Exercise-induced sweating in healthy subjects as a model to predict a drug's sweat-reducing properties in hyperhydrosis: a prospective, placebo-controlled, double-blind study by Harmsze, Ankie M, Houte, Marthe van, Deneer, Vera H M, Tupker, Ron A

“…The aim of this study was to develop a model to evaluate the efficacy of drugs with expected sweat-reducing properties in healthy subjects in order to select…”
Get full text